Rogini Balachandran

Dr. Rogini Balachandran

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 October 2019 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
RBRogini Balachandran
Rogini Balachandran
KJKristian Kiim Jensen
Kristian Kiim Jensen
JBJakob Burcharth
Jakob Burcharth
SESarah Ekeloef
Sarah Ekeloef
ASAnders Schack
Anders Schack
Ismail GögenurIsmail Gögenur
Ismail Gögenur

21 December 2023 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
RBRogini Balachandran
Rogini Balachandran
HTHenriette Vind Thaysen
Henriette Vind Thaysen
PCPeter Christensen
Peter Christensen
RZRobert Zachariae
Robert Zachariae
LILene Hjerrild Iversen
Lene Hjerrild Iversen
Background: Colorectal cancer with peritoneal metastases can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Treatment may result in biopsychosocial late effects (LEs). We explored the frequency and severity of the following biopsychosocial LEs: anxiety, depression, fear of cancer recurrence (FCR), insomnia, fatigue, cognitive impairment, and pain, and evaluated their impact on quality of life (QoL). Method: This was a national prospective cohort study screening for LEs during the period January 2021–May 2023. Patients completed the following questionnaires: General Anxiety Disorder-7, Patient Health Questionnaire-9, FCR Inventory-Short Form, Insomnia Severity Index, Functional Assessment of Chronic Illness Therapy-Fatigue, cognitive impairment (six items from the European Organisation for Research and Treatment of Cancer Item Library), and the Rectal Cancer Pain Score. Preregistration was completed at ClinicalTrials.gov (NCT04956107). Result: In total, 99 patients were included. The mean age was 61 years and 57% were women. At 3 months after surgery, the frequent LEs were fatigue (72%), FCR (58%), and pain (48%), and at 12 months after surgery, the frequent LEs were FCR (65%), fatigue (40%), and insomnia (33%). More than half of the patients (54%) reported at least two LEs after 12 months. Patients with moderate-to-severe LEs reported a lower QoL than patients with no/mild LEs. Patients with no/mild LEs had a similar QoL as the Danish norm population. Conclusion: Biopsychosocial LEs were prevalent. The QoL of patients reporting LEs in the worst severity categories was negatively impacted. Screening and treatment for these LEs should be a focus in cancer survivor follow-up.

25 February 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
RBRogini Balachandran
Rogini Balachandran
LMLouise Zinck Mogensen
Louise Zinck Mogensen
PCPeter Christensen
Peter Christensen
HTHenriette Vind Thaysen
Henriette Vind Thaysen
LILene Hjerrild Iversen
Lene Hjerrild Iversen

27 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RBRogini Balachandran
Rogini Balachandran
HTHenriette Vind Thaysen
Henriette Vind Thaysen
PCPeter Christensen
Peter Christensen
ENEva Rames Nissen
Eva Rames Nissen
MOMia Skytte O’toole
Mia Skytte O’toole
LILene Hjerrild Iversen
Lene Hjerrild Iversen
Background: Up to 80% of patients experience late effects (LE) one year after surgery for peritoneal metastases (PM) from colorectal cancer (CRC). We tested the feasibility and outcome of a treatment strategy to address LEs. Methods: During January 2021–May 2023, patients who had undergone surgery for CRC-PM in Denmark were screened for biopsychosocial LEs (anxiety, depression, fear of cancer recurrence, insomnia, cognitive impairment, pain, fatigue). Patients scoring according to clinical cut-offs were referred to a Multi-Disciplinary Team conference (MDT). The patients, surgeon(s), nurse(s), and psychologists participated in the MDT, identified key concerns and proposed a personalized intervention. Pre- and post-intervention, patients completed a “Measure Yourself Concerns and Wellbeing” (MYCaW) questionnaire, rating the two most distressing LEs and general wellbeing on a 7-point Likert scale. Results: Of 28 eligible patients, 13 (59 years (mean), 85% women) accepted referral, participated in the MDT, and were offered a personalized intervention. The intervention was completed by 11 patients. Improvement in MYCaW score was observed 1 month postintervention for all three items: (1) the primary LE (p = 0.003, Hedges’s g 1.54), (2) the secondary LE (p < 0.001, Hedges’s g 1.65), and (3) general wellbeing (p = 0.005, Hedges’s g 1.09). This improvement was sustained 6 months postintervention. The 15 non-participants were, in general, older (66 years (mean), men 73%). Conclusions: Screening for LEs and conducting an MDT can provide a personalized intervention plan, which patients are able to complete and may benefit from.

24 July 2023 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
RBRogini Balachandran
Rogini Balachandran
MSMette Møller Sørensen
Mette Møller Sørensen
JFJonas Amstrup Funder
Jonas Amstrup Funder
AKAnders Riegels Knudsen
Anders Riegels Knudsen
LILene Hjerrild Iversen
Lene Hjerrild Iversen
Objectives: Peritoneal metastases (PM) and liver metastases (LM) are present simultaneously in up to 2 % of patients at the time of their colorectal cancer (CRC) diagnosis. Curatively intended treatment includes cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) combined with LM resection. A less invasive treatment for LM is ablation. We aimed to estimate overall survival (OS), disease-free survival (DFS) and postoperative data in patients managed simultaneously with CRS, HIPEC and radiofrequency ablation (RFA) as first choice. Methods: This was a retrospective national cohort study. All patients were treated at Aarhus University Hospital; the only CRS+HIPEC centre in Denmark. We included CRC patients managed with curative intent for simultaneously diagnosed PM and LM in the period January 2016 – December 2021. LM was treated with RFA as first choice, if possible. Survival was calculated by the Kaplan-Meier method. Results: A total of 25 patients were included, the median age was 60 years (range 43–75 years) and 15 (60 %) were females. The median peritoneal cancer index was 7 (range 0–12), the median number of LM was 1 (range 1–3). Ablation was performed as the only treatment for LM in 18 (72 %) patients. After a median follow-up time of 17.1 months (range 4–36 months), the median OS was 28.6 months (95 % confidence interval (Cl) 15.8;36.1), 1-year OS was 84.0 % (95 % Cl 62.8;93.7). Median DFS was 6.1 months (95 % Cl 4.0;10.3). Median LOS was ten days (range 5–26 days). Both 30-day and 90-day mortality were 0 %. Conclusions: The selected treatment modality (RFA) for CRC patients with both LM and PM was safe. However, DFS was low. Further research is warranted to investigate if RFA is as effective as LM resection.